Physician profile
Jerry Leventhal
NPI 1558364265
$9,998.00
in general payments reported to CMS, 2019-2025
36 companies · $941 in 2025
The $941 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,044 · 2020: $3,139 · 2021: $1,072 · 2022: $760 · 2023: $1,131 · 2024: $911 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,948.49 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,271.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,018.33 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $916.11 | 2019-2021 | |
| Lilly USA, LLC | $775.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $621.39 | 2019-2025 | |
| Amgen INC. | $503.94 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $415.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $341.09 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $251.42 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $216.29 | 2019-2022 | |
| Allergan, INC. | $206.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $183.24 | 2019-2022 | |
| Exact Sciences Corporation | $170.77 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $168.40 | 2020-2023 | Nexletol |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Leventhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.